Josh Distler, Oak Hill Bio CEO
April 15, 2025 07:00 AM EDT
Startups
Deals
Pharma

Ex­clu­sive: A small biotech will bring Roche's An­gel­man drug back to life

Kyle LaHucik

Senior Reporter

Roche dev­as­tat­ed the An­gel­man syn­drome com­mu­ni­ty in 2023, when it end­ed clin­i­cal de­vel­op­ment of ru­gonersen, a treat­ment can­di­date …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Trump pledges his sup­port for a change to the IRA long sought by drug­mak­ers

Gly­comine rais­es $115M to see if it can treat rare gly­co­sy­la­tion dis­or­der

At ACIP hear­ing, CDC says it's 'scrap­ing' to re­spond to measles out­break; FDA com­ments on No­vavax halt

J&J's Du­a­to says 'not tar­iffs, but tax pol­i­cy' is best way to boost US man­u­fac­tur­ing

GeneDx to buy Fab­ric Ge­nomics for up to $51M

sponsored

New York-based part­ner­ship sets the stan­dard for ex­pand­ing clin­i­cal tri­al ac­cess for un­der­served and di­verse ...

A service from the Financial Times